Bexion Pharmaceuticals

bexion pharmaceuticals is committed to the discovery and clinical development of life-changing oncology treatments. we focus on helping patients and their families living with cancer, where there is a significant unmet need. bexion has initiated a robust clinical development plan to develop safe, effective treatments across multiple indications. our company founder and leadership team have deep experience across pharmaceutical operations, discovery, research and development, manufacturing, clinical, regulatory, and commercialization. the bexion team is driven by the promise of developing life-changing oncology therapies on our path to become a leading biotech company. bexion has received orphan drug designation from the u.s. food and drug administration (fda) for glioblastoma multiforme (gbm) and malignant glioma including diffuse intrinsic pontine giloma (dipg) to learn more about bexion pharmaceuticals, please visit bexionpharma.com or contact margaret m. van gilse at (859) 446-